SAB Biotherapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
SAB Biotherapeutics Free Cash Flow (FCF) History (SABS)
SAB Biotherapeutics reported −$45.7M in free cash flow for fiscal 2025, a decrease of $11.1M from the previous fiscal year.
View full SAB Biotherapeutics company overviewSAB Biotherapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$45.7M | −$11.1M | — | — |
| 2024 | 2024-12-31 | −$34.6M | −$9.3M | — | −2618.65% |
| 2023 | 2023-12-31 | −$25.3M | $309,366 | — | −1130.71% |
| 2022 | 2022-12-31 | −$25.6M | −$16.7M | — | −107.20% |
| 2021 | 2021-12-31 | −$9.0M | −$6.2M | — | −14.71% |
| 2020 | 2020-12-31 | −$2.7M | — | — | −4.94% |
SAB Biotherapeutics quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$11.4M | −$3.7M | — | — |
| Q1 2026 | 2026-03-31 | −$15.3M | −$4.4M | — | — |
| Q4 2024 | 2024-12-31 | −$9.6M | $3.9M | — | — |
| Q3 2024 | 2024-09-30 | −$6.4M | −$1.1M | — | −2429.28% |
| Q2 2024 | 2024-06-30 | −$7.8M | −$2.8M | — | −2952.95% |
| Q1 2024 | 2024-03-31 | −$10.9M | −$9.3M | — | −1151.74% |
| Q4 2023 | 2023-12-31 | −$13.5M | −$11.8M | — | −4430.85% |
| Q3 2023 | 2023-09-30 | −$5.3M | $2.7M | — | −414.49% |
| Q2 2023 | 2023-06-30 | −$4.9M | $139,034 | — | −5755.33% |
| Q1 2023 | 2023-03-31 | −$1.6M | $9.3M | — | −279.99% |
| Q4 2022 | 2022-12-31 | −$1.7M | $5.6M | — | −77.41% |
| Q3 2022 | 2022-09-30 | −$8.0M | −$8.6M | — | −222.78% |
| Q2 2022 | 2022-06-30 | −$5.1M | $4.8M | — | −79.69% |
| Q1 2022 | 2022-03-31 | −$10.9M | −$18.5M | — | −92.31% |
| Q4 2021 | 2021-12-31 | −$7.2M | — | — | −65.47% |
| Q3 2021 | 2021-09-30 | $569,315 | — | — | +3.88% |
| Q2 2021 | 2021-06-30 | −$9.8M | — | — | −54.09% |
| Q1 2021 | 2021-03-31 | $7.6M | — | — | +44.68% |
SAB Biotherapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$2.7M to −$45.7M, a net decrease of $43.0M. SAB Biotherapeutics's latest reported quarter, Q2 2026, generated −$11.4M in free cash flow, a decrease of $3.7M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review SAB Biotherapeutics filings at SEC.gov ↗